Get more information on Pharmacovigilance Market - Request Free Sample Report
The Pharmacovigilance market valued USD 7.20 billion in 2023, and estimated to reach USD 18.52 billion by 2032 with CAGR 11.09% over the forecast period 2024-2032.
The pharmacovigilance market is focused on ensuring drug safety and efficacy by meticulously monitoring and evaluating pharmaceutical products post-market release. This crucial process involves identifying, assessing, understanding, and preventing adverse drug reactions or other drug-related issues. By prioritizing patient safety and optimizing drug benefits, pharmacovigilance plays a pivotal role in enhancing overall healthcare outcomes.
For instance, the Indian Pharmacopoeia Commission, the National Coordination Centre for pharmacovigilance has its 30th skill development programme on pharmacovigilance scheduled for August 2024. As a part of this work, the IPC continues to expand its expertise status as a WHO collaborating centre.
Several factors drive a robust pharmacovigilance market with the growing occurrence of adverse drug reactions (ADRs), along with complexity in drug regimens for chronic diseases namely cancer, diabetes and other cardiovascular disorders is highly driving the demand. Use of medicines for chronic conditions in non-hospital settings (e.g., a WHO report 2017), Apart from the expanding drug development pipeline (including personalized medicines, biosimilars and orphan drugs), creating an increased demand for strict safety monitoring. The move towards decentralized clinical trials and adaptive trial designs is also further complicating matters which in turn is driving the demand for more comprehensive pharmacovigilance services suite.
Pharmacovigilance relies heavily on a robust data supply chain. Data originates from various sources including healthcare providers, patients, pharmaceutical companies, regulatory agencies, and public databases. Efficient data flow from these sources is crucial for timely and accurate safety assessments. However, challenges like data delays and inconsistencies can hinder pharmacovigilance effectiveness. Key performance indicators such as time to case creation, case completion rate, and data quality are essential for monitoring data supply chain performance.
Cost-saving and increasing operational pressures have made these pharmaceutical companies outsource certain functions of pharmacovigilance such as medical writing, data collection/reporting etc. Evidence of this trend advancing the pharmacovigilance market forward includes collaboration between major players IQVIA and Alibaba Cloud to deploy their clinical solutions in China.
The pharmacovigilance market is also highly fragmented with fast changing technological landscape. Harnessing big data, AI and cloud solutions as integrated concepts will reinvent the traditional approaches to pharmacovigilance. Compared to this, the creation of AI algorithms for signal detection (for a wide variety of data sources) is undoubtedly an innovative accomplishment.
The pharmacovigilance market is characterized by a dynamic competitive landscape, with mergers and acquisitions being a prevalent strategy for growth and expansion. However, Pharmalex GmbH's recent acquisition of Cpharm Australia has given a boost to its geographical presence and option services but the industry operates within a stringent regulatory environment, with bodies like the US FDA playing a crucial role in oversight. Growing ADR reporting demand likely to drive mounting regulatory compliance pressures on healthcare providers.
It can be concluded that the pharmacovigilance market will continue to grow in future as well and there are multiple factors responsible for this huge increase including high rate of drug consumption, increasing number of ADRs, advancement in technology and changing regulatory landscape.
Oracle, for instance, has significantly enhanced its Argus and Safety One Intake solutions with AI-powered features, demonstrating a strong commitment to technological innovation in drug safety.
The Pharmacovigilance Market Grows With Greater Public Attention
A growth in public and regulatory awareness related to drug safety helps a significant cause for the earnings growth of pharmaceutical companies that offers chance to rise pharmacovigilance market. Not only more people are learning about adverse drug reactions (ADRs), but there is a greater demand for stronger systems to monitor the safety of drugs. Therefore, the demand for an end-to-end pharmacovigilance solution is greater than ever.
Drivers- government initiatives to increase public awareness related to medication safety & proper use and the counteractive function of pharmacovigilance, Fannin developments are helping boost the demand for adventure travel. For example, campaigns led by the Uppsala Monitoring Centre and various national medicines regulatory authorities enrich public awareness and boost spontaneous ADR reporting.
This greater public participation in drug safety encourages a healthier pharmacovigilance network and increases market growth. Examples include investigations of collaborations between pharmaceutical companies and service providers to enlarge market capacities.
Growing adoption of pharmacovigilance outsourcing by pharmaceutical companies is favouring the expansion in global pharmacovigilance market. By outsourcing pharmacovigilance functions, pharma companies can focus their resources on core competencies and avail the benefits of economies of scale to substantially reduce operational costs leading to direct cost savings.
Outsourcing enables companies to pay full attention on their core competencies i.e. drug research & developing and commercialization while ensuring end-to-end processes, faster standards of efficiency as well as complying with regulations for best practices in the industry from external partners taking care at all levels of complete or any other degree needed drug safety monitoring service.
This, in turn, is aiding expansion of the global pharmacovigilance outsourcing market resultant to increased demand for such services.
In December 2023, Thermo Fisher Scientific introduced the CorEvitas Pharmacovigilance Platform for Clinical Research Registries.
In September 2023, Medac GmbH enhanced its drug safety monitoring capabilities through a partnership with ArisGlobal Solutions.
Concerns Regarding Funding And Uneven Healthcare Budget Distribution Negatively Impact On Pharmacovigilance Market Growth
There are many barriers to the pharmacovigilance market which may hamper its performance, such as lack of capital investment and scarcity of available professionals. Scarce financial resources are currently limiting the establishment of comprehensive drug safety monitoring systems, and affecting ability to address disease-specific challenges. In addition, lack of adequately trained personnel leads to delays in reporting adverse events/difficulties in performing safety monitoring and also results in poor regulatory compliances. Addressing the challenges mentioned above would entail major financial resources required for training and supporting these initiatives in pharmacovigilance.
Pre-clinical
Phase I
Phase II
Phase III
Phase IV
The post-marketing phase (Phase IV) dominated the pharmacovigilance market, accounted with 74.03% in 2023. This phase is crucial for detecting unexpected adverse drug reactions (ADRs) in a large patient population after drug commercialization.
While Phase IV led the market, the Phase III clinical trial segment is projected to experience significant growth and these trials provide essential data on drug efficacy, safety, and interactions before market launch. Industry players are investing in advanced trial management technologies to enhance efficiency and drive growth in this segment.
In-house
Contract Outsourcing
The contract outsourcing segment held the largest share of the pharmacovigilance market with 72% in 2023, driven by the surge in Contract Research Organizations (CROs) offering comprehensive clinical trial solutions, particularly in Asia-Pacific regions like India, China, and Japan. This segment is poised for rapid growth due to cost-effective, flexible, and high-quality services provided by outsourcing partners. Pharmacovigilance outsourcing now encompasses a wide array of complex services, including benefit-risk assessment, signal detection, pharmacoeconomic analysis, and risk management planning.
Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
Spontaneous reporting is the predominated method in pharmacovigilance, accounted for over 30% of the market in 2023. Its effectiveness in identifying new, serious, and rare adverse drug reactions (ADRs) at a relatively low cost has driven its widespread adoption by both regulatory authorities and pharmaceutical companies.
However, the targeted spontaneous reporting segment is projected to experience significant growth which is driven by initiatives from organizations like ENCePP, this method offers advantages such as cost-efficiency, feasibility in resource-limited settings, and utility in routine monitoring. These factors are expected to increase the demand for targeted spontaneous reporting in the future.
Case Data Management
Case Logging
Case Data Analysis
Medical Reviewing & Reporting
Signal Detection
Adverse Event Logging
Adverse Event Analysis
Adverse Event Review & Reporting
Risk Management System
Risk Evaluation System
Risk Mitigation System
Signal detection is led segment in the pharmacovigilance market with 39% in 2023 which involves identifying potential safety concerns by analyzing various data sources such as spontaneous reports, clinical trials, and real-world data.
The case data management segment is poised for rapid growth and this segment focuses on organizing and analyzing adverse event data from multiple sources, including spontaneous reports, clinical trials, and literature. Advanced technologies like artificial intelligence are being increasingly adopted to improve efficiency and extract valuable insights from this data.
Oncology
Neurology
Cardiology
Respiratory Systems
Others
The oncology segment was the largest with 70% in 2023 and fastest-growing sector within the pharmacovigilance market. Due to the complex nature of cancer treatments and the potential for severe adverse reactions, rigorous safety monitoring is crucial.
The increasing number of cancer research initiatives, coupled with significant government funding for oncology research (such as the U.S. Cancer Moonshot initiative), is driving the demand for specialized pharmacovigilance services in this area.
Pharmaceuticals
Biotechnology Companies
Medical Device Manufacturers
Others
Regional Analysis :
North America dominated the pharmacovigilance market with 60.01% in 2023, driven by a concentration of major pharmaceutical companies, stringent regulatory frameworks (like the FDA's REMS), and a high prevalence of drug-related issues. The U.S., in particular, is a major market due to its large drug consumption and rigorous regulatory oversight.
Europe is another key region, characterized by robust regulatory standards (e.g., EMA's RMP), a growing number of clinical trials, and increasing drug development activities. The region has witnessed a surge in adverse drug reaction reporting, emphasizing the need for robust pharmacovigilance.
The Asia Pacific region is emerging as a significant market due to its cost-effective clinical trial landscape and growing pharmaceutical industry. Countries like India, China, Singapore, and South Korea are becoming outsourcing hubs, attracting global pharma companies.
Need any customization research on Pharmacovigilance Market - Enquiry Now
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Key Players :
ArisGlobal,IQVIA, Accenture, Cognizant, IBM, Clinquest Group B.V. (Linical Americas), Laboratory Corporation of America Holdings, Capgemini, ICON plc., ITClinical, ClinChoice (formerly FMD K&L), TAKE Solutions Limited, Wipro, Parexel International (MA) Corporation, BioClinica Inc. (Clario), United BioSource LLC and others.
Companies like ICON plc is forming collaborations to accelerate clinical trial execution in specialized areas such as medical dermatology.
Organizations like Parexel are releasing industry insights and trends to support the biopharmaceutical industry in drug development.
Key players such as Oracle are incorporating AI into their pharmacovigilance solutions to enhance drug safety monitoring capabilities.
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.20 Bn |
| Market Size by 2032 | US$ 18.52 Bn |
| CAGR | CAGR of 11.09% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By product Life Cycle • By Service Provider • By Type • By Process Flow • By Therapeutic • By End Use |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | ArisGlobal, IQVIA Inc., Accenture, Cognizant, IBM, Clinquest Group B.V. (Linical Americas), Laboratory Corporation of America Holdings, Capgemini, ICON plc., ITClinical, ClinChoice (formerly FMD K&L), TAKE Solutions Limited, Wipro, Parexel International (MA) Corporation, BioClinica Inc. (Clario), United BioSource LLC, and others. |
| Key Drivers | • The Pharmacovigilance Market Grows With Greater Public Attention |
| Market Restraints | • Concerns Regarding Funding And Uneven Healthcare Budget Distribution Negatively Impact On Pharmacovigilance Market Growth |
Ans: The Pharmacovigilance Market is expected to grow at a CAGR of 11.09%.
Ans: The Pharmacovigilance Market size is estimated to reach USD 18.52 Bn by 2032.
Ans: The North American region held the largest market share of 60.01% in 2023 and will continue to dominate the market.
Ans: The constant evaluation and assessment of the benefit-risk profiles of drugs depend heavily on pharmacovigilance
Ans: Pharmacovigilance seeks to recognise and comprehend ADRs, evaluate their frequency and seriousness, and take the necessary steps to reduce their incidence and adverse effects on patient health.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenge
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Pharmacovigilance Market Segmentation, By Product Life Cycle
7.1 Introduction
7.2 Pre-clinical
7.3 Phase I
7.4 Phase II
7.5 Phase III
7.6 Phase IV
8. Pharmacovigilance Market Segmentation, By Service Provider
8.1 Introduction
8.2 In-house
8.3 Contract Outsourcing
9. Pharmacovigilance Market Segmentation, By Type
9.1 Introduction
9.2 Spontaneous Reporting
9.3 Intensified ADR Reporting
9.4 Targeted Spontaneous Reporting
9.5 Cohort Event Monitoring
9.6 EHR Mining
10. Pharmacovigilance Market Segmentation, By Process Flow
10.1 Introduction
10.2 Case Data Management
10.2.1 Case Logging
10.2.2 Case Data Analysis
10.2.3 Medical Reviewing & Reporting
10.3 Signal Detection
10.3.1 Adverse Event Logging
10.3.2 Adverse Event Analysis
10.3.3 Adverse Event Review & Reporting
10.4 Risk Management System
10.4.1 Risk Evaluation System
10.4.2 Risk Mitigation System
11. Pharmacovigilance Market Segmentation, By Therapeutic Area
11.1 Introduction
11.2 Oncology
11.3 Neurology
11.4 Cardiology
11.5 Respiratory Systems
11.6 Others
12. Pharmacovigilance Market Segmentation, By End Use
12.1 Introduction
12.2 Pharmaceuticals
12.3 Biotechnology Companies
12.4 Medical Device Manufacturers
12.5 Others
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 Trend Analysis
13.2.2 North America Pharmacovigilance Market By Country
13.2.3 North America Pharmacovigilance Market By Product Life Cycle
13.2.4 North America Pharmacovigilance Market By Service Provider
13.2.5 North America Pharmacovigilance Market By Type
13.2.6 North America Pharmacovigilance Market, By Process Flow
13.2.7 North America Pharmacovigilance Market, By Therapeutic Area
13.2.8 North America Pharmacovigilance Market, By End Use
13.2.9 USA
13.2.9.1 USA Pharmacovigilance Market By Product Life Cycle
13.2.9.2 USA Pharmacovigilance Market By Service Provider
13.2.9.3 USA Pharmacovigilance Market By Type
13.2.9.4 USA Pharmacovigilance Market, By Process Flow
13.2.9.5 USA Pharmacovigilance Market, By Therapeutic Area
13.2.9.6 USA Pharmacovigilance Market, By End Use
13.2.10 Canada
13.2.10.1 Canada Pharmacovigilance Market By Product Life Cycle
13.2.10.2 Canada Pharmacovigilance Market By Service Provider
13.2.10.3 Canada Pharmacovigilance Market By Type
13.2.10.4 Canada Pharmacovigilance Market, By Process Flow
13.2.10.5 Canada Pharmacovigilance Market, By Therapeutic Area
13.2.10.6 Canada Pharmacovigilance Market, By End Use
13.2.11 Mexico
13.2.11.1 Mexico Pharmacovigilance Market By Product Life Cycle
13.2.11.2 Mexico Pharmacovigilance Market By Service Provider
13.2.11.3 Mexico Pharmacovigilance Market By Type
13.2.11.4 Mexico Pharmacovigilance Market, By Process Flow
13.2.11.5 Mexico Pharmacovigilance Market, By Therapeutic Area
13.2.11.6 Mexico Pharmacovigilance Market, By End Use
13.3 Europe
13.3.1 Trend Analysis
13.3.2 Eastern Europe
13.3.2.1 Eastern Europe Pharmacovigilance Market By Country
13.3.2.2 Eastern Europe Pharmacovigilance Market By Product Life Cycle
13.3.2.3 Eastern Europe Pharmacovigilance Market By Service Provider
13.3.2.4 Eastern Europe Pharmacovigilance Market By Type
13.3.2.5 Eastern Europe Pharmacovigilance Market By Process Flow
13.3.2.6 Eastern Europe Pharmacovigilance Market, By Therapeutic Area
13.3.2.7 Eastern Europe Pharmacovigilance Market, By End Use
13.3.2.8 Poland
13.3.2.8.1 Poland Pharmacovigilance Market By Product Life Cycle
13.3.2.8.2 Poland Pharmacovigilance Market By Service Provider
13.3.2.8.3 Poland Pharmacovigilance Market By Type
13.3.2.8.4 Poland Pharmacovigilance Market By Process Flow
13.3.2.8.5 Poland Pharmacovigilance Market, By Therapeutic Area
13.3.2.8.6 Poland Pharmacovigilance Market, By End Use
13.3.2.9 Romania
13.3.2.9.1 Romania Pharmacovigilance Market By Product Life Cycle
13.3.2.9.2 Romania Pharmacovigilance Market By Service Provider
13.3.2.9.3 Romania Pharmacovigilance Market By Type
13.3.2.9.4 Romania Pharmacovigilance Market By Process Flow
13.3.2.9.5 Romania Pharmacovigilance Market, By Therapeutic Area
13.3.2.9.6 Romania Pharmacovigilance Market, By End Use
13.3.2.10 Hungary
13.3.2.10.1 Hungary Pharmacovigilance Market By Product Life Cycle
13.3.2.10.2 Hungary Pharmacovigilance Market By Service Provider
13.3.2.10.3 Hungary Pharmacovigilance Market By Type
13.3.2.10.4 Hungary Pharmacovigilance Market By Process Flow
13.3.2.10.5 Hungary Pharmacovigilance Market, By Therapeutic Area
13.3.2.10.6 Hungary Pharmacovigilance Market, By End Use
13.3.2.11 Turkey
13.3.2.11.1 Turkey Pharmacovigilance Market By Product Life Cycle
13.3.2.11.2 Turkey Pharmacovigilance Market By Service Provider
13.3.2.11.3 Turkey Pharmacovigilance Market By Type
13.3.2.11.4 Turkey Pharmacovigilance Market By Process Flow
13.3.2.11.5 Turkey Pharmacovigilance Market, By Therapeutic Area
13.3.2.11.6 Turkey Pharmacovigilance Market, By End Use
13.3.2.12 Rest of Eastern Europe
13.3.2.12.1 Rest of Eastern Europe Pharmacovigilance Market By Product Life Cycle
13.3.2.12.2 Rest of Eastern Europe Pharmacovigilance Market By Service Provider
13.3.2.12.3 Rest of Eastern Europe Pharmacovigilance Market By Type
13.3.2.12.4 Rest of Eastern Europe Pharmacovigilance Market By Process Flow
13.3.2.12.5 Rest of Eastern Europe Pharmacovigilance Market, By Therapeutic Area
13.3.2.12.6 Rest of Eastern Europe Pharmacovigilance Market, By End Use
13.3.3 Western Europe
13.3.3.1 Western Europe Pharmacovigilance Market By Country
13.3.3.2 Western Europe Pharmacovigilance Market By Product Life Cycle
13.3.3.3 Western Europe Pharmacovigilance Market By Service Provider
13.3.3.4 Western Europe Pharmacovigilance Market By Type
13.3.3.5 Western Europe Pharmacovigilance Market By Process Flow
13.3.3.6 Western Europe Pharmacovigilance Market, By Therapeutic Area
13.3.3.7 Western Europe Pharmacovigilance Market, By End Use
13.3.3.8 Germany
13.3.3.8.1 Germany Pharmacovigilance Market By Product Life Cycle
13.3.3.8.2 Germany Pharmacovigilance Market By Service Provider
13.3.3.8.3 Germany Pharmacovigilance Market By Type
13.3.3.8.4 Germany Pharmacovigilance Market By Process Flow
13.3.3.8.5 Germany Pharmacovigilance Market, By Therapeutic Area
13.3.3.8.6 Germany Pharmacovigilance Market, By End Use
13.3.3.9 France
13.3.3.9.1 France Pharmacovigilance Market By Product Life Cycle
13.3.3.9.2 France Pharmacovigilance Market By Service Provider
13.3.3.9.3 France Pharmacovigilance Market By Type
13.3.3.9.4 France Pharmacovigilance Market By Process Flow
13.3.3.9.5 France Pharmacovigilance Market, By Therapeutic Area
13.3.3.9.6 France Pharmacovigilance Market, By End Use
13.3.3.10 UK
13.3.3.10.1 UK Pharmacovigilance Market By Product Life Cycle
13.3.3.10.2 UK Pharmacovigilance Market By Service Provider
13.3.3.10.3 UK Pharmacovigilance Market By Type
13.3.3.10.4 UK Pharmacovigilance Market By Process Flow
13.3.3.10.5 UK Pharmacovigilance Market, By Therapeutic Area
13.3.3.10.6 UK Pharmacovigilance Market, By End Use
13.3.3.11 Italy
13.3.3.11.1 Italy Pharmacovigilance Market By Product Life Cycle
13.3.3.11.2 Italy Pharmacovigilance Market By Service Provider
13.3.3.11.3 Italy Pharmacovigilance Market By Type
13.3.3.11.4 Italy Pharmacovigilance Market By Process Flow
13.3.3.11.5 Italy Pharmacovigilance Market, By Therapeutic Area
13.3.3.11.6 Italy Pharmacovigilance Market, By End Use
13.3.3.12 Spain
13.3.3.12.1 Spain Pharmacovigilance Market By Product Life Cycle
13.3.3.12.2 Spain Pharmacovigilance Market By Service Provider
13.3.3.12.3 Spain Pharmacovigilance Market By Type
13.3.3.12.4 Spain Pharmacovigilance Market By Process Flow
13.3.3.12.5 Spain Pharmacovigilance Market, By Therapeutic Area
13.3.3.12.6 Spain Pharmacovigilance Market, By End Use
13.3.3.13 Netherlands
13.3.3.13.1 Netherlands Pharmacovigilance Market By Product Life Cycle
13.3.3.13.2 Netherlands Pharmacovigilance Market By Service Provider
13.3.3.13.3 Netherlands Pharmacovigilance Market By Type
13.3.3.13.4 Netherlands Pharmacovigilance Market By Process Flow
13.3.3.13.5 Netherlands Pharmacovigilance Market, By Therapeutic Area
13.3.3.13.6 Netherlands Pharmacovigilance Market, By End Use
13.3.3.14 Switzerland
13.3.3.14.1 Switzerland Pharmacovigilance Market By Product Life Cycle
13.3.3.14.2 Switzerland Pharmacovigilance Market By Service Provider
13.3.3.14.3 Switzerland Pharmacovigilance Market By Type
13.3.3.14.4 Switzerland Pharmacovigilance Market By Process Flow
13.3.3.14.5 Switzerland Pharmacovigilance Market, By Therapeutic Area
13.3.3.14.6 Switzerland Pharmacovigilance Market, By End Use
13.3.3.15 Austria
13.3.3.15.1 Austria Pharmacovigilance Market By Product Life Cycle
13.3.3.15.2 Austria Pharmacovigilance Market By Service Provider
13.3.3.15.3 Austria Pharmacovigilance Market By Type
13.3.3.15.4 Austria Pharmacovigilance Market By Process Flow
13.3.3.15.5 Austria Pharmacovigilance Market, By Therapeutic Area
13.3.3.15.6 Austria Pharmacovigilance Market, By End Use
13.3.3.16 Rest of Western Europe
13.3.3.16.1 Rest of Western Europe Pharmacovigilance Market By Product Life Cycle
13.3.3.16.2 Rest of Western Europe Pharmacovigilance Market By Service Provider
13.3.3.16.3 Rest of Western Europe Pharmacovigilance Market By Type
13.3.3.16.4 Rest of Western Europe Pharmacovigilance Market By Process Flow
13.3.3.16.5 Rest of Western Europe Pharmacovigilance Market, By Therapeutic Area
13.3.3.16.6 Rest of Western Europe Pharmacovigilance Market, By End Use
13.4 Asia-Pacific
13.4.1 Trend Analysis
13.4.2 Asia-Pacific Pharmacovigilance Market By country
13.4.3 Asia-Pacific Pharmacovigilance Market By Product Life Cycle
13.4.4 Asia-Pacific Pharmacovigilance Market By Service Provider
13.4.5 Asia-Pacific Pharmacovigilance Market By Type
13.4.6 Asia-Pacific Pharmacovigilance Market By Process Flow
13.4.7 Asia-Pacific Pharmacovigilance Market, By Therapeutic Area
13.4.8 Asia-Pacific Pharmacovigilance Market, By End Use
13.4.9 China
13.4.9.1 China Pharmacovigilance Market By Product Life Cycle
13.4.9.2 China Pharmacovigilance Market By Service Provider
13.4.9.3 China Pharmacovigilance Market By Type
13.4.9.4 China Pharmacovigilance Market By Process Flow
13.4.9.5 China Pharmacovigilance Market, By Therapeutic Area
13.4.9.6 China Pharmacovigilance Market, By End Use
13.4.10 India
13.4.10.1 India Pharmacovigilance Market By Product Life Cycle
13.4.10.2 India Pharmacovigilance Market By Service Provider
13.4.10.3 India Pharmacovigilance Market By Type
13.4.10.4 India Pharmacovigilance Market By Process Flow
13.4.10.5 India Pharmacovigilance Market, By Therapeutic Area
13.4.10.6 India Pharmacovigilance Market, By End Use
13.4.11 Japan
13.4.11.1 Japan Pharmacovigilance Market By Product Life Cycle
13.4.11.2 Japan Pharmacovigilance Market By Service Provider
13.4.11.3 Japan Pharmacovigilance Market By Type
13.4.11.4 Japan Pharmacovigilance Market By Process Flow
13.4.11.5 Japan Pharmacovigilance Market, By Therapeutic Area
13.4.11.6 Japan Pharmacovigilance Market, By End Use
13.4.12 South Korea
13.4.12.1 South Korea Pharmacovigilance Market By Product Life Cycle
13.4.12.2 South Korea Pharmacovigilance Market By Service Provider
13.4.12.3 South Korea Pharmacovigilance Market By Type
13.4.12.4 South Korea Pharmacovigilance Market By Process Flow
13.4.12.5 South Korea Pharmacovigilance Market, By Therapeutic Area
13.4.12.6 South Korea Pharmacovigilance Market, By End Use
13.4.13 Vietnam
13.4.13.1 Vietnam Pharmacovigilance Market By Product Life Cycle
13.4.13.2 Vietnam Pharmacovigilance Market By Service Provider
13.4.13.3 Vietnam Pharmacovigilance Market By Type
13.4.13.4 Vietnam Pharmacovigilance Market By Process Flow
13.4.13.5 Vietnam Pharmacovigilance Market, By Therapeutic Area
13.4.13.6 Vietnam Pharmacovigilance Market, By End Use
13.4.14 Singapore
13.4.14.1 Singapore Pharmacovigilance Market By Product Life Cycle
13.4.14.2 Singapore Pharmacovigilance Market By Service Provider
13.4.14.3 Singapore Pharmacovigilance Market By Type
13.4.14.4 Singapore Pharmacovigilance Market By Process Flow
13.4.14.5 Singapore Pharmacovigilance Market, By Therapeutic Area
13.4.14.6 Singapore Pharmacovigilance Market, By End Use
13.4.15 Australia
13.4.15.1 Australia Pharmacovigilance Market By Product Life Cycle
13.4.15.2 Australia Pharmacovigilance Market By Service Provider
13.4.15.3 Australia Pharmacovigilance Market By Type
13.4.15.4 Australia Pharmacovigilance Market By Process Flow
13.4.15.5 Australia Pharmacovigilance Market, By Therapeutic Area
13.4.15.6 Australia Pharmacovigilance Market, By End Use
13.4.16 Rest of Asia-Pacific
13.4.16.1 Rest of Asia-Pacific Pharmacovigilance Market By Product Life Cycle
13.4.16.2 Rest of Asia-Pacific Pharmacovigilance Market By Service Provider
13.4.16.3 Rest of Asia-Pacific Pharmacovigilance Market By Type
13.4.16.4 Rest of Asia-Pacific Pharmacovigilance Market By Process Flow
13.4.16.5 Rest of Asia-Pacific Pharmacovigilance Market, By Therapeutic Area
13.4.16.6 Rest of Asia-Pacific Pharmacovigilance Market, By End Use
13.5 Middle East & Africa
13.5.1 Trend Analysis
13.5.2 Middle East
13.5.2.1 Middle East Pharmacovigilance Market By Country
13.5.2.2 Middle East Pharmacovigilance Market By Product Life Cycle
13.5.2.3 Middle East Pharmacovigilance Market By Service Provider
13.5.2.4 Middle East Pharmacovigilance Market By Type
13.5.2.5 Middle East Pharmacovigilance Market By Process Flow
13.5.2.6 Middle East Pharmacovigilance Market, By Therapeutic Area
13.5.2.7 Middle East Pharmacovigilance Market, By End Use
13.5.2.8 UAE
13.5.2.8.1 UAE Pharmacovigilance Market By Product Life Cycle
13.5.2.8.2 UAE Pharmacovigilance Market By Service Provider
13.5.2.8.3 UAE Pharmacovigilance Market By Type
13.5.2.8.4 UAE Pharmacovigilance Market By Process Flow
13.5.2.8.5 UAE Pharmacovigilance Market, By Therapeutic Area
13.5.2.8.6 UAE Pharmacovigilance Market, By End Use
13.5.2.9 Egypt
13.5.2.9.1 Egypt Pharmacovigilance Market By Product Life Cycle
13.5.2.9.2 Egypt Pharmacovigilance Market By Service Provider
13.5.2.9.3 Egypt Pharmacovigilance Market By Type
13.5.2.9.4 Egypt Pharmacovigilance Market By Process Flow
13.5.2.9.5 Egypt Pharmacovigilance Market, By Therapeutic Area
13.5.2.9.6 Egypt Pharmacovigilance Market, By End Use
13.5.2.10 Saudi Arabia
13.5.2.10.1 Saudi Arabia Pharmacovigilance Market By Product Life Cycle
13.5.2.10.2 Saudi Arabia Pharmacovigilance Market By Service Provider
13.5.2.10.3 Saudi Arabia Pharmacovigilance Market By Type
13.5.2.10.4 Saudi Arabia Pharmacovigilance Market By Process Flow
13.5.2.10.5 Saudi Arabia Pharmacovigilance Market, By Therapeutic Area
13.5.2.10.6 Saudi Arabia Pharmacovigilance Market, By End Use
13.5.2.11 Qatar
13.5.2.11.1 Qatar Pharmacovigilance Market By Product Life Cycle
13.5.2.11.2 Qatar Pharmacovigilance Market By Service Provider
13.5.2.11.3 Qatar Pharmacovigilance Market By Type
13.5.2.11.4 Qatar Pharmacovigilance Market By Process Flow
13.5.2.11.5 Qatar Pharmacovigilance Market, By Therapeutic Area
13.5.2.11.6 Qatar Pharmacovigilance Market, By End Use
13.5.2.12 Rest of Middle East
13.5.2.12.1 Rest of Middle East Pharmacovigilance Market By Product Life Cycle
13.5.2.12.2 Rest of Middle East Pharmacovigilance Market By Service Provider
13.5.2.12.3 Rest of Middle East Pharmacovigilance Market By Type
13.5.2.12.4 Rest of Middle East Pharmacovigilance Market By Process Flow
13.5.2.12.5 Rest of Middle East Pharmacovigilance Market, By Therapeutic Area
13.5.2.12.6 Rest of Middle East Pharmacovigilance Market, By End Use
13.5.3 Africa
13.5.3.1 Africa Pharmacovigilance Market By Country
13.5.3.2 Africa Pharmacovigilance Market By Product Life Cycle
13.5.3.3 Africa Pharmacovigilance Market By Service Provider
13.5.3.4 Africa Pharmacovigilance Market By Type
13.5.3.5 Africa Pharmacovigilance Market By Process Flow
13.5.3.6 Africa Pharmacovigilance Market, By Therapeutic Area
13.5.3.7 Africa Pharmacovigilance Market, By End Use
13.5.3.8 Nigeria
13.5.3.8.1 Nigeria Pharmacovigilance Market By Product Life Cycle
13.5.3.8.2 Nigeria Pharmacovigilance Market By Service Provider
13.5.3.8.3 Nigeria Pharmacovigilance Market By Type
13.5.3.8.4 Nigeria Pharmacovigilance Market By Process Flow
13.5.3.8.5 Nigeria Pharmacovigilance Market, By Therapeutic Area
13.5.3.8.6 Nigeria Pharmacovigilance Market, By End Use
13.5.3.9 South Africa
13.5.3.9.1 South Africa Pharmacovigilance Market By Product Life Cycle
13.5.3.9.2 South Africa Pharmacovigilance Market By Service Provider
13.5.3.9.3 South Africa Pharmacovigilance Market By Type
13.5.3.9.4 South Africa Pharmacovigilance Market By Process Flow
13.5.3.9.5 South Africa Pharmacovigilance Market, By Therapeutic Area
13.5.3.9.6 South Africa Pharmacovigilance Market, By End Use
13.5.3.10 Rest of Africa
13.5.3.10.1 Rest of Africa Pharmacovigilance Market By Product Life Cycle
13.5.3.10.2 Rest of Africa Pharmacovigilance Market By Service Provider
13.5.3.10.3 Rest of Africa Pharmacovigilance Market By Type
13.5.3.10.4 Rest of Africa Pharmacovigilance Market By Process Flow
13.5.3.10.5 Rest of Africa Pharmacovigilance Market, By Therapeutic Area
13.5.3.10.6 Rest of Africa Pharmacovigilance Market, By End Use
13.6 Latin America
13.6.1 Trend Analysis
13.6.2 Latin America Pharmacovigilance Market By country
13.6.3 Latin America Pharmacovigilance Market By Product Life Cycle
13.6.4 Latin America Pharmacovigilance Market By Service Provider
13.6.5 Latin America Pharmacovigilance Market By Type
13.6.6 Latin America Pharmacovigilance Market By Process Flow
13.6.7 Latin America Pharmacovigilance Market, By Therapeutic Area
13.6.8 Latin America Pharmacovigilance Market, By End Use
13.6.9 Brazil
13.6.9.1 Brazil Pharmacovigilance Market By Product Life Cycle
13.6.9.2 Brazil Pharmacovigilance Market By Service Provider
13.6.9.3 Brazil Pharmacovigilance Market By Type
13.6.9.4 Brazil Pharmacovigilance Market By Process Flow
13.6.9.5 Brazil Pharmacovigilance Market, By Therapeutic Area
13.6.9.6 Brazil Pharmacovigilance Market, By End Use
13.6.10 Argentina
13.6.10.1 Argentina Pharmacovigilance Market By Product Life Cycle
13.6.10.2 Argentina Pharmacovigilance Market By Service Provider
13.6.10.3 Argentina Pharmacovigilance Market By Type
13.6.10.4 Argentina Pharmacovigilance Market By Process Flow
13.6.10.5 Argentina Pharmacovigilance Market, By Therapeutic Area
13.6.10.6 Argentina Pharmacovigilance Market, By End Use
13.6.11 Colombia
13.6.11.1 Colombia Pharmacovigilance Market By Product Life Cycle
13.6.11.2 Colombia Pharmacovigilance Market By Service Provider
13.6.11.3 Colombia Pharmacovigilance Market By Type
13.6.11.4 Colombia Pharmacovigilance Market By Process Flow
13.6.11.5 Colombia Pharmacovigilance Market, By Therapeutic Area
13.6.11.6 Colombia Pharmacovigilance Market, By End Use
13.6.12 Rest of Latin America
13.6.12.1 Rest of Latin America Pharmacovigilance Market By Product Life Cycle
13.6.12.2 Rest of Latin America Pharmacovigilance Market By Service Provider
13.6.12.3 Rest of Latin America Pharmacovigilance Market By Type
13.6.12.4 Rest of Latin America Pharmacovigilance Market By Process Flow
13.6.12.5 Rest of Latin America Pharmacovigilance Market, By Therapeutic Area
13.6.12.6 Rest of Latin America Pharmacovigilance Market, By End Use
14 Company Profiles
14.1 ArisGlobal
14.1.1 Company Overview
14.1.2 Financial
14.1.3 Products/ Services Offered
14.1.4 The SNS View
14.2 IQVIA Inc.
14.2.1 Company Overview
14.2.2 Financial
14.2.3 Products/ Services Offered
14.2.4 The SNS View
14.3 Accenture
14.3.1 Company Overview
14.3.2 Financial
14.3.3 Products/ Services Offered
14.3.4 The SNS View
14.4 Cognizant
14.4.1 Company Overview
14.4.2 Financial
14.4.3 Products/ Services Offered
14.4.4 The SNS View
14.5 IBM
14.5.1 Company Overview
14.5.2 Financial
14.5.3 Products/ Services Offered
14.5.4 The SNS View
14.6 Clinquest Group B.V. (Linical Americas)
14.6.1 Company Overview
14.6.2 Financial
14.6.3 Products/ Services Offered
14.6.4 The SNS View
14.7 Laboratory Corporation of America Holdings
14.7.1 Company Overview
14.7.2 Financial
14.7.3 Products/ Services Offered
14.7.4 The SNS View
14.8 Capgemini
14.8.1 Company Overview
14.8.2 Financial
14.8.3 Products/ Services Offered
14.8.4 The SNS View
14.9 ICON plc.
14.9.1 Company Overview
14.9.2 Financial
14.9.3 Products/ Services Offered
14.9.4 The SNS View
14.10 ITClinical
14.10.1 Company Overview
14.10.2 Financial
14.10.3 Products/ Services Offered
14.10.4 The SNS View
15. Competitive Landscape
15.1 Competitive Benchmarking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. Use Case and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Human Insulin Market size was valued at USD 19.21 billion in 2023 and is expected to reach USD 24.71 billion by 2031 and grow at a CAGR of 3.2% over the forecast period of 2024-2031.
The Clear Aligners Market size was estimated at USD 3.3 billion in 2022 and is expected to reach USD19.04 billion by 2030 with a growing CAGR of 24.5% during the forecast period of 2023-2030.
The Cardiology Information System (CIS) Market Size was valued at USD 1.09 billion in 2023 and is expected to reach USD 2.24 billion by 2031 and grow at a CAGR of 9.4% over the forecast period 2024-2031.
The Protein Engineering Market size was estimated USD 2.2 billion in 2022 and is expected to reach USD 7.5 billion by 2030 at a CAGR of 16.7% during the forecast period of 2023-2030.
The Precision Medicine Software Market Size was valued at USD 1.85 billion in 2023, and is expected to reach USD 4.49 billion by 2031 and grow at a CAGR of 11.7% over the forecast period 2024-2031.
The Healthcare Information Technology Market Size was valued at USD 229.43 billion in 2023, and is expected to reach USD 1827.12 billion by 2031 and grow at a CAGR of 29.61% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
